BTIG Research restated a “buy” rating and issued a $65.00 target price on shares of Rapport Therapeutics in a report on Wednesday, August 5th. Get Rapport Therapeutics alerts:Check Out Our Latest Analysis on Rapport TherapeuticsRapport Therapeutics Stock Down 2.2%Shares of NASDAQ:RAPP traded down $1.07 during trading on Wednesday, reaching $47.75. Meeder Asset Management Inc. acquired a new stake in Rapport Therapeutics during the fourth quarter valued at approximately $37,000. Rapport Therapeutics Company Profile(Get Free Report)Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. Further ReadingReceive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.